Ruijin Hospital: clinical-trial pipeline
Ruijin Hospital is the sponsor of 667 clinical trials in ClinicalTrials.gov and the EU CTIS portal; 350 are not yet finished and 29 were first posted in the last 90 days. Source: Arcadium Data, data as of .
Open trials350
Phase 2/3 and 339
Countries1
New in 90 days29
Trials by phase
| Phase | Trials |
|---|---|
| Not applicable | 378 |
| Phase 2 | 128 |
| Phase 4 | 37 |
| Phase 1 | 34 |
| Phase 1/2 | 31 |
| Phase 3 | 27 |
| Early phase 1 | 20 |
| Phase 2/3 | 12 |
Trials by status
| Status | Trials |
|---|---|
| Unknown | 217 |
| Recruiting | 194 |
| Not yet recruiting | 125 |
| Completed | 86 |
| Active, not recruiting | 31 |
| Withdrawn or not authorised | 7 |
| Terminated | 6 |
| Suspended or halted | 1 |
Condition areas
| Area | Trials |
|---|---|
| Oncology | 363 |
| Gastroenterology and liver | 81 |
| Cardiovascular | 55 |
| Neurology | 51 |
| Respiratory | 39 |
| Infectious disease and vaccines | 38 |
| Metabolic and endocrine (diabetes, obesity) | 25 |
| Rare and genetic diseases | 23 |
| Nephrology and urology | 20 |
| Immunology and rheumatology | 17 |
| Psychiatry and mental health | 16 |
| Ophthalmology | 10 |
Countries
| Country | Trials |
|---|---|
| China | 573 |
Latest changes
| Day | Change | Trial |
|---|---|---|
| 2026-10-22 | New trial posted | A Prospective, Multicenter, Portable Pulmonary Function Comparison Study Aimed at Evaluat… |
| 2026-10-22 | New trial posted | Anakinra for Prevention of Poor Graft Function in MDS Allo-HSCT |
| 2026-10-22 | New trial posted | Urinary Cell-Free DNA Liquid Biopsy for Urothelial Cancer Diagnosis and Origin Identifica… |
| 2026-10-22 | New trial posted | Temporal Interference Stimulation in Major Depressive Disorder: A Pilot Feasibility Study |
| 2026-10-22 | New trial posted | Adebrelimab Plus Famitinib as Adjuvant Therapy in Non-pCR NSCLC |
| 2026-10-22 | New trial posted | Modular Robot-Assisted Versus Conventional Minimally Invasive Esophagectomy for Esophagea… |
| 2026-10-22 | New trial posted | SCRT + Fruquintinib + Tislelizumab + CAPOX Versus SCRT + Tislelizumab + CAPOX as Neoadjuv… |
| 2026-10-22 | New trial posted | Efficacy and Safety of Obinutuzumab Beta in Primary IgA Nephropathy With Active Pathologi… |
| 2026-10-21 | New trial posted | Efficacy and Safety of Ivonescimab Plus Pemetrexed and Platinum-Based Chemotherapy in Adv… |
| 2026-10-21 | New trial posted | Integrated ¹⁸F-PSMA-1007 PET/MR Combined With Diffusion-Relaxation Correlation Spectrum I… |
| 2026-10-21 | New trial posted | Safety and Preliminary Antitumor Activity of Ivonescimab Plus Pemetrexed and Platinum-Bas… |
| 2026-10-21 | New trial posted | Real-World Use of Tarlatamab in Chinese Patients With Small-Cell Lung Cancer |
Open trials
The 25 most recently changed open trials.
| Registry id | Title | Phase | Status | Countries |
|---|---|---|---|---|
| NCT06826885 | Safety and Efficacy of IMPT or IMRT for Breast Cancer | Not applicable | Recruiting | China |
| NCT06365671 | CAR-T Following ASCT for Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma (R/R B-NHL) With High-Risk Prognos… | Phase 2 | Recruiting | China |
| NCT06646666 | ARTA-based Chemo-free Bridging/Maintenance Therapy in CAR-T Treatment for High-Risk R/R B-NHL Ineligible for… | Phase 2 | Not yet recruiting | China |
| NCT05675813 | Genotype-guided Treatment in Newly Diagnosed PTCL | Phase 1/2 | Recruiting | China |
| NCT06818084 | TRanscAtheter TreatMent of PurE Aortic Regurgitation With VitaFlow Liberty System | Phase 4 | Recruiting | China |
| NCT06876688 | Relma-cel Followed by Tislelizumab for the Treatment of Relapsed/Refractory CNS Large B-Cell Lymphoma | Phase 2 | Recruiting | China |
| NCT07824492 | Transcutaneous Regulation for Atrial Prevention in Postoperative Atrial Fibrillation Following OPCAB | Not applicable | Not yet recruiting | |
| NCT06644287 | The Value of 68Ga-grazytracer PET in Monitoring Responses to Immunotherapy of Advanced Soft Tissue Sarcomas | Not applicable | Recruiting | China |
| NCT06697418 | The Effect of Physical Activity Level Evaluated by Wrist-wearable Devices on Cardiovascular Disease Risk and… | Not applicable | Recruiting | China |
| NCT07184697 | Efficacy and Safety of Task-specific, Biomarker-driven, HD-ctACS inTRD. | Not applicable | Active, not recruiting | China |
| NCT07543107 | Verification of Range Accuracy and Correlation With Clinical Toxicity Using Offline PET/CT for Hypofractionat… | Not applicable | Not yet recruiting | |
| NCT03829553 | Hypofractionated Irradiation At Regional Nodal Area for Breast Cancer Vs Existed Standard Treatment | Phase 3 | Recruiting | China |
| NCT07004647 | MT027 Cell Injection in Patients With Advanced Primary or Secondary Peritoneal Tumors | Not applicable | Recruiting | China |
| NCT06901999 | Methotrexate or Thiotepa Combined With R-CHOP and Orelabrutinib in CNSL Patients | Phase 2 | Not yet recruiting | |
| NCT07337356 | Research on the Development and Validation of an Early Prediction Model for Delirium | Not applicable | Not yet recruiting | |
| NCT07556640 | LM-302 and S-1 Plus Intraperitoneal Paclitaxel With or Without Cadonilimab for Claudin 18.2-positive Gastric… | Phase 2 | Recruiting | China |
| NCT07548255 | The Efficacy and Safety of Sonrotoclax, Zanubrutinib Combined With Obinutuzumab in MCL | Phase 1 | Not yet recruiting | China |
| NCT07450963 | Cadonilimab Combined With RT in LACC Patients Ineligible for CCRT | Phase 2 | Not yet recruiting | |
| NCT07279584 | Golidocitinib Combined With GemOx in RR PTCL | Phase 2 | Not yet recruiting | |
| NCT07883382 | An Exploratory Study on the Use of Gecacitinib in Patients With Myeloid Malignancies and Myelofibrosis During… | Phase 1/2 | Not yet recruiting | China |
| NCT07745790 | Safety and Efficacy of Multimodal Thermal Therapy (MTT) Combined With KRAS G12V mRNA Vaccine, S-1, and Sintil… | Phase 2 | Not yet recruiting | China |
| NCT07525024 | KSD-101 in Patients With EBV-associated Hematological Malignancies | Not applicable | Not yet recruiting | China |
| NCT06114225 | Pulmonary Resectable Osteosarcoma Treated by Metastasectomy and Pre-operative Immunotherapy and Stereotactic… | Phase 2 | Recruiting | China |
| NCT06641856 | Respiratory Virome Diversity and Baseline Immunity in Healthy Individuals in Shanghai | Not applicable | Recruiting | China |
| NCT06062641 | Selinexor Combined With R-GDP Regimen for TP53-altered R/R DLBCL | Phase 2 | Not yet recruiting | China |
All sponsors: clinical-trial pipeline by sponsor.
Track a sponsor's pipeline
The API returns the same trials by sponsor website, phase, status, condition and country with a change feed, joined to hiring and public contract awards. Try it without a key on one sponsor.
Sources: ClinicalTrials.gov (U.S. National Library of Medicine, public domain) and the EU Clinical Trials Information System public portal (European Medicines Agency), data as of 2026-10-25. A trial that one register cites in the other is shown once. Organisation-level data only: investigators, contact persons and site names are not stored, and a sponsor that could be a private person is withheld. Sponsor-to-website matches are made by name and can be wrong; check the register before relying on a record. Independent of the NLM, NIH and EMA.
Cite as: Arcadium Data, "Ruijin Hospital clinical trials: 350 open, 39 in phase 3", https://arcadiumdata.io/clinical-trials/sponsor/ruijin-hospital/, data as of 2026-10-25.